Beijing, China

Minmin Liang

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 6.9

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Minmin Liang: Innovator in Targeted Drug Delivery Systems

Introduction: Minmin Liang is an accomplished inventor based in Beijing, China, who has made significant contributions to the field of biophysics and targeted medicinal therapies. With a focused approach on innovations in drug delivery systems, Liang's work aims to enhance the effectiveness of cancer treatments.

Latest Patents: Liang holds a patent titled "Drug carrier for tumor-specific targeted drug delivery and use thereof." This patent provides a detailed disclosure of a tumor-targeted drug delivery system that includes a specialized drug carrier made from full heavy-chain human ferritin. The invention outlines a method for preparing this drug delivery system by depolymerizing the ferritin, adding a tumor-treating drug, and re-polymerizing the resultant compound to form nanoparticles. This innovative approach promises to improve the specificity and efficacy of cancer therapies.

Career Highlights: Minmin Liang is affiliated with the Institute of Biophysics, Chinese Academy of Sciences, where he has been instrumental in conducting pioneering research in drug delivery systems. His work is guided by a commitment to advancing scientific understanding and enhancing patient outcomes in oncology.

Collaborations: Liang collaborates with talented colleagues in his field, including Xiyun Yan and Kelong Fan. Their combined expertise has fostered a collaborative environment that enhances research and innovation in targeted therapies.

Conclusion: Minmin Liang exemplifies the spirit of innovation as an inventor dedicated to improving cancer treatment methodologies. Through his groundbreaking patent and collaborative efforts, he is helping to shape the future of targeted drug delivery systems, potentially transforming the landscape of cancer therapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…